Home/Filings/4/0001870913-24-000016
4//SEC Filing

Shanmugam Muthusamy 4

Accession 0001870913-24-000016

CIK 0001023024other

Filed

Apr 21, 8:00 PM ET

Accepted

Apr 22, 6:26 PM ET

Size

8.8 KB

Accession

0001870913-24-000016

Insider Transaction Report

Form 4
Period: 2024-04-18
Shanmugam Muthusamy
DirectorHEAD OF R&D, COO-NOVITIUM OPS
Transactions
  • Sale

    Common Stock

    2024-04-19$65.17/sh16,809$1,095,443782,620 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-04-18$64.98/sh10,423$677,287799,429 total(indirect: By LLC)
Holdings
  • Common Stock

    68,652
  • Common Stock

    (indirect: By LLC)
    5,000
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
  • [F2]The shares were sold in multiple trades at prices ranging from $64.43 to $65.89. The price reported above reflects the weighted average sales price.
  • [F3]The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
  • [F4]The shares were sold in multiple trades at prices ranging from $64.20 to $65.79. The price reported above reflects the weighted average sales price.
  • [F5]The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Issuer

ANI PHARMACEUTICALS INC

CIK 0001023024

Entity typeother

Related Parties

1
  • filerCIK 0001870913

Filing Metadata

Form type
4
Filed
Apr 21, 8:00 PM ET
Accepted
Apr 22, 6:26 PM ET
Size
8.8 KB